论文部分内容阅读
目的分析围绝经期子宫肌瘤患者采用小剂量米非司酮与孕三烯酮联合方案治疗的疗效。方法围绝经期子宫肌瘤患者100例,随机分成2组:对照组50例,单纯给予小剂量米非司酮经口服用药治疗;观察组50例,在对照组基础上加用孕三烯酮联合治疗。治疗后比较2组疗效与不良反应。结果观察组治疗总有效率为96.0%,高于对照组的70.0%,差异有统计学意义(P<0.05)。与治疗前相比,2组患者治疗后的雌激素水平、孕激素水平均有显著降低,血红蛋白水平均有显著上升,差异有统计学意义(P<0.05);2组患者治疗3月后的子宫体积和肌瘤体积均有显著降低,差异有统计学意义(P<0.05)。观察组出现绝经期症状患者与对照组差异无统计学意义。结论围绝经期子宫肌瘤患者采用小剂量米非司酮与孕三烯酮联合方案治疗疗效显著,安全性较高,值得进一步推广。
Objective To analyze the curative effect of low dose mifepristone combined with gestrinone in patients with perimenopausal uterine fibroids. Methods 100 cases of perimenopausal uterine fibroids were randomly divided into two groups: control group of 50 cases, only given a small dose of mifepristone oral medication; observation group of 50 patients on the basis of the control group plus gestrinone Combination therapy. After treatment, the efficacy and adverse reactions of the two groups were compared. Results The total effective rate of observation group was 96.0%, which was higher than that of control group (70.0%), the difference was statistically significant (P <0.05). Compared with those before treatment, the levels of estrogen and progesterone in both groups were significantly decreased and the levels of hemoglobin were significantly increased (P <0.05). After 2 months of treatment, Uterine volume and fibroid volume were significantly lower, the difference was statistically significant (P <0.05). There was no significant difference between the observation group and the control group in the incidence of menopausal symptoms. Conclusion The treatment of menopausal uterine fibroids with low-dose combination of mifepristone and gestrinone has obvious curative effect, high safety and worthy of further promotion.